Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) chairman Gabriele Cerrone tells Proactive London's Andrew Scott they're planning to spin out its StemPrintER and SPARE genomics-based personalised medicine businesses as a separate stock market quoted company. Cerrone says Tiziana shareholders will benefit from holding shares in both Tiziana, which has a rapidly developing drug portfolio, while also realising the standalone value of the StemPrintER operation as it progresses through its own development milestones.
Tiziana Life Sciences to spin out StemPrintER to 'maximise its value'
Quick facts: Tiziana Life Sciences PLC
Price: 143.65 GBX
Market Cap: £274.6 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE